Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
Date:4/22/2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy

and New Insights into Mechanism of Action of Nitazoxanide

MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week.

"These new studies confirm earlier data suggesting synergistic activity between nitazoxanide and peginterferon in genotype 4 patients and provide a first look at sustained virologic response in a limited number of genotype 1 patients," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and discoverer of nitazoxanide. "These data also provide interesting insights into the mechanism of action of nitazoxanide and confirm previous findings related to its safety."

The four presentations include:

-- An oral presentation, titled, "Randomized Controlled Trial of

Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and

Peginterferon-Ribavirin in the Treatment of Patients with Chronic

Hepatitis C Genotype 4," reported final 24-week post-treatment

sustained virologic response (SVR) rates for the company's STEALTH C-1

trial.

In the trial, 96 treatment-naive patients with chronic hepatitis C

genotype 4 were randomized into three groups to receive either 48 weeks

of standard of care (SOC) treatment (n=40), 12 weeks of nitazoxanide

followed by 36 weeks of nitazoxanide plus peginterferon (a dual regimen,

n=28), or 12 weeks of nitazoxanide followed by 36 weeks of nitazoxanide

plus SOC with peginterferon plus ribavirin (a triple regimen, n=28). An

additional 24 interferon-experi
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 /PRNewswire/ ... HOLD -- FN Media Group LLC, PIV757417 The ... Focus on Developing Orphan Drug Products & Treatments ... now OFF HOLD. Distribution time: 3 Aug 2015 ... agreements between biotech companies, military surgical research and ...
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... Japan and FLORHAM PARK, N.J. ... announced that once-daily naldemedine met its primary and secondary ... the treatment of opioid-induced constipation (OIC) in adult patients ... peripherally acting mu-opioid receptor antagonist (PAMORA). This is the ... primary and key secondary endpoints. Study results ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Jan. 10, 2011 CoreLab Partners, Inc , ... Inc and Medifacts International, has launched a new advanced ... are pleased to announce the release of our proprietary ... development continuum by offering sponsors advanced technologies and integrated ...
... Underwriters Laboratories (UL), a world ... release of a white paper that addresses the current ... equipment. The white paper, "Home Healthcare Equipment: An ... highlights the unique challenges for manufacturers with the U.S. ...
Cached Medicine Technology:CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3UL White Paper Examines Key Implications of Growing Home Healthcare Industry 2
(Date:8/3/2015)... ... 03, 2015 , ... Bayer has agreed to pay $56.9 million to set ... claimant alleged to have suffered an arterial blood clot including stroke and heart attack. ... and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed against ...
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... that while an overwhelming number of Hispanics believe people can positively affect their ... percent of participants queried said making diet changes was important. Far fewer participants ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... and fitness site and the largest online retailer of nutritional supplements, has ... Sports is up for 11 awards in the following categories:, ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3
... adults may have high blood pressure, according to an analysis ... which is supported by the National Institutes of Health. ... men and women between 24 and 32 years of age ... was conducted by Kathleen Mullan Harris, Ph.D., principal investigator of ...
... HealthDay Reporter , WEDNESDAY, May 25 (HealthDay News) ... just as effective at restoring stroke patients, walking ability ... a new study indicates. The results also defy ... demonstrating that patients who began rehabilitation even six months ...
... (HealthDay News) -- The Internet has put the world at ... banned or controlled substances to slip within their grasp, British ... 19 in Drug Testing and Analysis , looked at ... other than those claimed and can be hazardous. These products ...
... may program a woman,s baby for future diabetes, even if ... University of Illinois study published in the Journal of ... diet before birth modifies gene expression in the livers of ... can cause early insulin resistance and diabetes," said Yuan-Xiang Pan, ...
... , WEDNESDAY, May 25 (HealthDay News) -- ... experience are more likely to have a greater decrease ... brain critical to learning and memory, new research finds. ... were a "born-again" Protestant or Catholic, or conversely, those ...
... have faced a baffling riddle: how to unravel a disorder that ... Now a UCLA study is the first ... level, resulting in an autistic brain that differs dramatically in structure ... edition of Nature , the findings provide new insight into ...
Cached Medicine News:Health News:Study shows 19 percent of young adults have high blood pressure 2Health News:Study shows 19 percent of young adults have high blood pressure 3Health News:Stroke Patients May Regain Function Just as Easily at Home 2Health News:Stroke Patients May Regain Function Just as Easily at Home 3Health News:Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds 2Health News:High-fat diet during pregnancy programs child for future diabetes 2Health News:Being 'Born-Again' Linked to More Brain Atrophy: Study 2Health News:Autism changes molecular structure of the brain, UCLA study finds 2Health News:Autism changes molecular structure of the brain, UCLA study finds 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: